Search results for "drug resistance"

showing 10 items of 953 documents

Verifying a medical protocol with temporal graphs: the case of a nosocomial disease.

2014

Abstract Objective Our contribution focuses on the implementation of a formal verification approach for medical protocols with graphical temporal reasoning paths to facilitate the understanding of verification steps. Materials and methods Formal medical guideline specifications and background knowledge are represented through conceptual graphs, and reasoning is based on graph homomorphism. These materials explain the underlying principles or rationale that guide the functioning of verifications. Results An illustration of this proposal is made using a medical protocol defining guidelines for the monitoring and prevention of nosocomial infections. Such infections, which are acquired in the h…

Model checking[ INFO.INFO-MO ] Computer Science [cs]/Modeling and SimulationComputation tree logicTheoretical computer scienceComputer scienceModel checking Medical protocolMédecine humaine et pathologieCritical Care and Intensive Care MedicineMedical guidelineConsistency (database systems)Clinical Protocols[ SDV.MHEP ] Life Sciences [q-bio]/Human health and pathologyDrug Resistance BacterialHumansFormal verificationProblem SolvingProtocol (science)Cross Infectionbusiness.industryVisual informationModels TheoreticalModélisation et simulationNosocomial diseases[INFO.INFO-MO]Computer Science [cs]/Modeling and SimulationConceptual graphsCatheter-Related InfectionsConceptual graphCarrier StateVisual modelingDisease SusceptibilitySoftware engineeringbusiness[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyAlgorithmsJournal of critical care
researchProduct

Modulation of P-glycoprotein activity by novel synthetic curcumin derivatives in sensitive and multidrug-resistant T-cell acute lymphoblastic leukemi…

2016

Abstract Background Multidrug resistance (MDR) and drug transporter P-glycoprotein (P-gp) represent major obstacles in cancer chemotherapy. We investigated 19 synthetic curcumin derivatives in drug-sensitive acute lymphoblastic CCRF–CEM leukemia cells and their multidrug-resistant P-gp-overexpressing subline, CEM/ADR5000. Material and methods Cytotoxicity was tested by resazurin assays. Doxorubicin uptake was assessed by flow cytometry. Binding modes of compounds to P-gp were analyzed by molecular docking. Chemical features responsible for bioactivity were studied by quantitative structure activity relationship (QSAR) analyses. A 7-descriptor QSAR model was correlated with doxorubicin uptak…

Models Molecular0301 basic medicineCurcuminCell SurvivalT cellQuantitative Structure-Activity RelationshipAntineoplastic AgentsPharmacologyPrecursor T-Cell Lymphoblastic Leukemia-LymphomaToxicologyFlow cytometry03 medical and health sciences0302 clinical medicineCell Line TumormedicineHumansDoxorubicinATP Binding Cassette Transporter Subfamily B Member 1CytotoxicityP-glycoproteinPharmacologybiologymedicine.diagnostic_testChemistrymedicine.diseaseDrug Resistance MultipleMultiple drug resistanceLeukemia030104 developmental biologymedicine.anatomical_structureDoxorubicinDrug Resistance NeoplasmCell culture030220 oncology & carcinogenesisbiology.proteinmedicine.drugToxicology and Applied Pharmacology
researchProduct

Heterocyclic and Phenyl Double-Bond-Locked Combretastatin Analogues Possessing Potent Apoptosis-inducing activity in HL60 and in MDR Cell lines

2005

Two new series of combretastatin (CA-4) analogues have been prepared. The alkenyl motif of CA-4 was replaced either by a five-membered heterocyclic (isoxazoline or isoxazole) or by a six-membered ring (pyridine or benzene). The new compounds have been evaluated for their effects on tubulin assembly and for cytotoxic and apoptotic activities. Five compounds (18b, 20a, 21a, 34b, and 35b) demonstrated an attractive profile of cytotoxicity (IC501 microM) and apoptosis-inducing activity but poor antitubulin activity. The isoxazoline derivatives 18b, 20a, and 21a, demonstrated potent apoptotic activity different from that of natural CA-4. Their ability to block most cells in the G2 phase suggests…

Models MolecularA-4 ANALOGSDouble bondHL60StereochemistryPyridinesTUBULINApoptosisANTINEOPLASTIC AGENTSchemistry.chemical_compoundStructure-Activity RelationshipCell Line TumorDrug DiscoveryStilbenesBenzene DerivativesHumansIsoxazoleBIOLOGICAL EVALUATIONCytotoxicitychemistry.chemical_classificationCombretastatinbiologyCOLCHICINEDEATHIsoxazolesDrug Resistance MultipleTubulinANTIMITOTIC ANTITUMOR AGENTSMULTIDRUGchemistryApoptosisCell cultureDrug Resistance NeoplasmDISCOVERYbiology.proteinMolecular MedicineDrug Screening Assays AntitumorSOLID TUMOR-THERAPY
researchProduct

Cytotoxicity of Novel Sulfanilamides Towards Sensitive and Multidrugresistant Leukemia Cells

2014

Novel sulfa Schiff bases were synthesized and characterized by a reaction between aromatic sulfonamides and aromatic aldehydes or heterocyclic ketones in equimolar ratios. Their cytotoxicity was evaluated by the resazurin assay towards human sensitive CCRF-CEM and multidrug-resistant CEM/ADR5000 leukemia cells. Three of the tested compounds viz., 4-(anthracen-9-ylmethyleneamino)-N-(pyrimidin-2-yl)benzenesulfonamide (4), 4-(anthracen-9- ylmethyleneamino)benzenesulfonamide, (5) and 4-((3-phenylallylidene)amino)benzene-sulfonamide, (6) were cytotoxic (IC 50 values: 5.38-19.96 µM). CEM/ADR5000 cells were not cross-resistant to these compounds, indicating activity against otherwise drug-resistan…

Models MolecularCell SurvivalStereochemistryBiochemistrychemistry.chemical_compoundSulfanilamideCell Line TumorSulfanilamidesDrug DiscoverymedicineHumansCytotoxic T cellDoxorubicinATP Binding Cassette Transporter Subfamily B Member 1Homology modelingCytotoxicityPharmacologyLeukemiaChemistryOrganic ChemistryResazurinSulfanilamidemedicine.diseaseProtein Structure TertiaryLeukemiaDoxorubicinDrug Resistance NeoplasmMolecular MedicineVerapamilmedicine.drugCurrent Medicinal Chemistry
researchProduct

Targeting the Class A Carbapenemase GES-5 via Virtual Screening

2020

The worldwide spread of &beta

Models MolecularDrugantibiotic resistanceGES-5Antibiotic resistancemedia_common.quotation_subjectIn silicoDrug Evaluation Preclinicallcsh:QR1-502Guyana extended-spectrum-β-lactamaseMicrobial Sensitivity TestsComputational biologyBiologyBiochemistrybeta-LactamasesArticlelcsh:Microbiologyguyana extended-spectrum-β-lactamasecarbapenemase03 medical and health sciencesAntibiotic resistanceBacterial ProteinsDrug Resistance BacterialHumansAntibiotic resistance; GES-5; Guyana extended-spectrum-β-lactamase; carbapenemase; virtual screening; docking; noncovalent inhibitionges-5noncovalent inhibitionMolecular Biology030304 developmental biologymedia_common0303 health sciencesVirtual screening030306 microbiologyAntibiotic resistance; Carbapenemase; Docking; GES-5; Guyana extended-spectrum-β-lactamase; Noncovalent inhibition; Virtual screeningHit to leadvirtual screeningAntimicrobialAnti-Bacterial AgentsCarbapenemsdockingBiomolecules
researchProduct

Molecular dynamics studies on HIV-1 protease: a comparison of the flap motions between wild type protease and the M46I/G51D double mutant

2007

The emergence of drug-resistant mutants of HIV-1 is a tragic effect associated with conventional long-treatment therapies against acquired immunodeficiency syndrome. These mutations frequently involve the aspartic protease encoded by the virus; knowledge of the molecular mechanisms underlying the conformational changes of HIV-1 protease mutants may be useful in developing more effective and longer lasting treatment regimes. The flap regions of the protease are the target of a particular type of mutations occurring far from the active site. These mutations modify the affinity for both substrate and ligands, thus conferring resistance. In this work, molecular dynamics simulations were perform…

Models MolecularGromacs 3.2Anti-HIV AgentsProtein Conformationmedicine.medical_treatmentflap motionMutantCatalysisVirusInorganic ChemistryProtein structureHIV ProteaseHIV-1 proteaseDrug Resistance ViralEnzyme StabilityHIV-1 proteasemedicineHumansComputer SimulationPhysical and Theoretical Chemistrychemistry.chemical_classificationProteasebiologyHIV-1 drug-resistant mutantOrganic ChemistryWild typeActive siteRecombinant ProteinsComputer Science ApplicationsCell biologyEnzymemolecular dynamics simulationAmino Acid SubstitutionComputational Theory and MathematicsBiochemistrychemistryMutationHIV-1biology.protein
researchProduct

Docking and multivariate methods to explore HIV-1 drug-resistance: a comparative analysis

2007

In this paper we describe a comparative analysis between multivariate and docking methods in the study of the drug resistance to the reverse transcriptase and the protease inhibitors. In our early papers we developed a simple but efficient method to evaluate the features of compounds that are less likely to trigger resistance or are effective against mutant HIV strains, using the multivariate statistical procedures PCA and DA. In the attempt to create a more solid background for the prediction of susceptibility or resistance, we carried out a comparative analysis between our previous multivariate approach and molecular docking study. The intent of this paper is not only to find further supp…

Models MolecularMultivariate statisticsMultivariate analysisAnti-HIV AgentsCombined useHuman immunodeficiency virus (HIV)Computational biologyDrug resistanceBiologyLigandsBioinformaticsmedicine.disease_causeHIV ProteaseMolecular descriptorDrug Resistance ViralDrug DiscoverymedicineHumansDOCKINGPhysical and Theoretical ChemistryBinding SitesHIV Protease InhibitorsSettore CHIM/08 - Chimica FarmaceuticaHIV Reverse TranscriptaseComputer Science ApplicationsDRUG RESISTANCEDocking (molecular)Drug DesignMultivariate AnalysisMutationHIV-1Computer-Aided DesignReverse Transcriptase InhibitorsMultivariate statisticalJournal of Computer-Aided Molecular Design
researchProduct

In-silico screening of new potential Bcl-2/Bcl-xl inhibitors as apoptosis modulators

2008

One of the major problems in the fight against cancer is drug-resistance, which, at a molecular level, can be acquired through mutations able to deactivate apoptosis. In particular, proteins in the Bcl-2 family are central regulators of programmed cell death, and members that inhibit apoptosis, such as Bcl-xl and Bcl-2, are overexpressed in many tumours. The development of new inhibitors of these proteins as potential anticancer therapeutics represents a new frontier. In this work, we carried out an in-silico screening of compounds from a free database of more than 2 million structures (ZINC database), which allowed us to identify 17 sulfonamide derivatives as new potential inhibitors; thes…

Models MolecularProgrammed cell deathDatabases FactualIn silicobcl-X ProteinAntineoplastic AgentsApoptosisBcl-xLDrug resistanceBiologyCatalysisInorganic ChemistryNeoplasmsmedicineAnimalsHumansPhysical and Theoretical ChemistryOrganic ChemistrySulfonamide (medicine)CancerApoptosis Bcl-2 Bcl-xl Inhibitors Molecular dockingmedicine.diseaseSettore CHIM/08 - Chimica FarmaceuticaMolecular medicineComputer Science ApplicationsCell biologyComputational Theory and MathematicsDrug Resistance NeoplasmApoptosisCancer researchbiology.proteinDrug Screening Assays Antitumormedicine.drugJournal of Molecular Modeling
researchProduct

RNA nucleotide methylation

2011

Methylation of RNA occurs at a variety of atoms, nucleotides, sequences and tertiary structures. Strongly related to other posttranscriptional modifications, methylation of different RNA species includes tRNA, rRNA, mRNA, tmRNA, snRNA, snoRNA, miRNA, and viral RNA. Different catalytic strategies are employed for RNA methylation by a variety of RNA-methyltransferases which fall into four superfamilies. This review outlines the different functions of methyl groups in RNA, including biophysical, biochemical and metabolic stabilization of RNA, quality control, resistance to antibiotics, mRNA reading frame maintenance, deciphering of normal and altered genetic code, selenocysteine incorporation,…

Models MolecularRNA methylationRNA-dependent RNA polymeraseRNA ArchaealBiologyMethylationBiochemistryRNA TransferDrug Resistance BacterialRNA Processing Post-TranscriptionalMolecular BiologyGeneticstRNA MethyltransferasesBinding SitesIntronRNANon-coding RNARNA BacterialRNA silencingRNA RibosomalRNA editingProtein BiosynthesisBiocatalysisNucleic Acid ConformationRNARNA ViralSmall nuclear RNAWIREs RNA
researchProduct

Development of Bimetallic Titanocene−Ruthenium−Arene Complexes As Anticancer Agents: Relationships between Structural and Biological Properties

2010

A series of bimetallic titanium-ruthenium complexes of general formula [(η(5)-C(5)H(5))(μ-η(5):κ(1)-C(5)H(4)(CR(2))(n)PR'R'')TiCl(2)](η(6)-p-cymene)RuCl(2) (n = 0, 1, 2 or 4; R = H or Me; R' = H, Ph, or Cy; R'' = Ph or Cy) have been synthesized, including two novel compounds as well as two cationic derivatives of formula [(η(5)-C(5)H(5))(μ-η(5):κ(1)-C(5)H(4)(CH(2))(n)PPh(2))TiCl(2)] [(η(6)-p-cymene)RuCl](BF(4)) (n = 0 or 2). The solid state structure of two of these compounds was also established by X-ray crystallography. The complexes showed a cytotoxic effect on human ovarian cancer cells and were markedly more active than their Ti or Ru monometallic analogues titanocene dichloride and RA…

Models MolecularStereochemistrychemistry.chemical_elementAntineoplastic AgentsCrystal structureCrystallography X-RayRutheniumCathepsin BMetalStructure-Activity Relationshipchemistry.chemical_compoundCoordination ComplexesCell Line TumorDrug DiscoveryAnimalsHumansBimetallic stripAlkylTitaniumchemistry.chemical_classificationCationic polymerizationTitanocene dichlorideRutheniumEnzymechemistryDrug Resistance Neoplasmvisual_artvisual_art.visual_art_mediumMolecular MedicineCattleDrug Screening Assays AntitumorProtein BindingJournal of Medicinal Chemistry
researchProduct